Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetWages, Salaries and Other
Ratios

Celldex Therapeutics (CLDX) Leases (2019 - 2025)

Celldex Therapeutics has reported Leases over the past 7 years, most recently at $2.4 million for Q4 2025.

  • Quarterly results put Leases at $2.4 million for Q4 2025, down 37.48% from a year ago — trailing twelve months through Dec 2025 was $2.4 million (down 37.48% YoY), and the annual figure for FY2025 was $2.4 million, down 37.48%.
  • Leases for Q4 2025 was $2.4 million at Celldex Therapeutics, down from $2.7 million in the prior quarter.
  • Over the last five years, Leases for CLDX hit a ceiling of $4.0 million in Q4 2022 and a floor of $2.2 million in Q1 2024.
  • Median Leases over the past 5 years was $3.1 million (2021), compared with a mean of $3.1 million.
  • Biggest five-year swings in Leases: crashed 40.41% in 2024 and later soared 62.31% in 2025.
  • Celldex Therapeutics' Leases stood at $3.0 million in 2021, then surged by 34.71% to $4.0 million in 2022, then tumbled by 35.59% to $2.6 million in 2023, then soared by 51.26% to $3.9 million in 2024, then crashed by 37.48% to $2.4 million in 2025.
  • The last three reported values for Leases were $2.4 million (Q4 2025), $2.7 million (Q3 2025), and $3.1 million (Q2 2025) per Business Quant data.